Holen Sie sich die Stockscreener-App
11.54
3.27%
-0.39
Handel nachbörslich:
12.11
0.57
+4.94%
Schlusskurs vom Vortag:
$11.93
Offen:
$11.76
24-Stunden-Volumen:
440.75K
Relative Volume:
1.04
Marktkapitalisierung:
$617.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.39M
KGV:
-3.1274
EPS:
-3.69
Netto-Cashflow:
$-123.06M
1W Leistung:
-5.80%
1M Leistung:
+1.27%
6M Leistung:
-0.35%
1J Leistung:
-2.70%
1-Tages-Spanne:
$11.05
$11.76
1-Wochen-Bereich:
$11.05
$12.58
52-Wochen-Spanne:
$7.30
$15.50
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Firmenname
Kalvista Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 999-0075
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie KALV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
11.54 | 617.72M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-12-18 | Eingeleitet | BofA Securities | Buy |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-29 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-20 | Eingeleitet | Needham | Buy |
| 2018-10-30 | Eingeleitet | Jefferies | Buy |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph
KalVista Set for Key Investor Presentation: What to Expect from Needham Conference - Stock Titan
KONFIDENT-KID trial of sebetralstat is now fully enrolled - Angioedema News
Cantor Fitzgerald maintains Overweight on Kalvista shares By Investing.com - Investing.com Australia
KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial - Yahoo Finance
Stifel maintains Buy on Kalvista stock, price target steady at $39 By Investing.com - Investing.com South Africa
Stifel maintains Buy on Kalvista stock, price target steady at $39 - Investing.com Australia
Cantor Fitzgerald maintains Overweight on Kalvista shares - Investing.com India
Kalvista stock holds as JMP reiterates $19 target By Investing.com - Investing.com Australia
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Bank of New York Mellon Corp - Defense World
Kalvista stock holds as JMP reiterates $19 target - Investing.com India
KalVista completes enrollment for pediatric HAE trial By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial - MarketScreener
KalVista completes enrollment for pediatric HAE trial - Investing.com India
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial - Marketscreener.com
Breakthrough Pediatric HAE Drug Trial Hits Major Milestone: Patient Demand Surges 50% - Stock Titan
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $23.80 Average Target Price from Analysts - Defense World
(KALV) Technical Pivots with Risk Controls - news.stocktradersdaily.com
H.C. Wainwright maintains Buy on Kalvista, $20 target By Investing.com - Investing.com Canada
KalVista Pharmaceuticals’ (KALV) Buy Rating Reiterated at HC Wainwright - Armenian Reporter
H.C. Wainwright maintains Buy on Kalvista, $20 target - Investing.com India
KalVista Pharmaceuticals Stock (KALV): Advancements in HAE Treatment and Regulatory Progress - Value the Markets
HC Wainwright Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV) - Defense World
Needham & Company LLC Reiterates “Buy” Rating for KalVista Pharmaceuticals (NASDAQ:KALV) - Defense World
Buy Rating for KalVista Pharmaceuticals Driven by Anticipated FDA Approval and Strong Market Position - TipRanks
Sebetralstat provides early, fast relief for HAE attacks: Data - Angioedema News Today
Jefferies cuts Kalvista stock price target to $31 from $33 - Investing.com
Jefferies cuts Kalvista stock price target to $31 from $33 By Investing.com - Investing.com Canada
KalVista Pharmaceuticals Advances Sebetralstat for HAE - TipRanks
KalVista Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Kalvista Pharmaceuticals Inc reports results for the quarter ended January 31Earnings Summary - TradingView
KALVISTA PHARMACEUTICALS Earnings Results: $KALV Reports Quarterly Earnings - Nasdaq
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - Business Wire
Reviewing KalVista Pharmaceuticals (NASDAQ:KALV) and Hillstream BioPharma (NASDAQ:HILS) - Defense World
KalVista Pharmaceuticals CEO sells $79,827 in stock By Investing.com - Investing.com Australia
KalVista Pharmaceuticals CEO sells $79,827 in stock - Investing.com
KalVista Pharmaceuticals CEO Sells Shares to Cover Tax Obligations - TradingView
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema - The Bakersfield Californian
Kalvista Pharmaceuticals Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
JMP Securities sets $19 target for Kalvista Pharmaceuticals stock - MSN
JMP reiterates Kalvista stock with $19 target, sees market growth - MSN
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Joplin Globe
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting - BioSpace
Sebetralstat shows promise in treating HAE attacks By Investing.com - Investing.com Canada
Sebetralstat shows promise in treating HAE attacks - Investing.com India
Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):